Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Alternext  >  Biocorp    ALCOR   FR0012788065

BIOCORP

(ALCOR)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

BIOCORP : Wins Pharmapack Award For Its New Generation Auto Injector Onejet

share with twitter share with LinkedIn share with facebook
02/07/2018 | 12:17pm EDT

Regulatory News:

BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA‐PME), a French company specializing in the development and manufacturing of innovative medical and drug delivery devices, announces today that its new device Onejet has won the Patient Safety and Convenience Award attributed by Pharmapack Europe 2018.

Onejet is the first motor driven, disposable and Bluetooth connected auto injector compatible with standard primary containers. Its motorization can be adjusted to any biologics density, allowing Onejet to easily deliver highly viscous drugs.

Injection data (time, doses and date) are transferred to a mobile app via Bluetooth, allowing monitoring of key treatment information. Connectivity is made possible thanks to an innovative and effortless pairing system requiring a simple confirmation from patient.

Onejet enhances BIOCORP’s connected devices range designed for modern healthcare. The global biologicals drugs market is increasing since those drugs are used to treat chronic diseases such as cancer, severe blood disorders and other auto immune diseases. Transparent Market Research forecasts a 10% annual growth rate: the market was US$ 210 billion in 2016 and is relied to ascend to US$ 480 billion by 2024(1).

Onejet answers an unmet need of pharmaceutical companies requiring an auto injection device flexible enough to deal with different containers and viscosities, starting from the early clinical trials stage. Onejet offers in a single mechanical platform an easy to use device, in a compact design with the advanced functionalities of ‘’smart’’ platforms including motor driven injection system, calibration of injection speed and force, and connectivity.

‘’Our whole team is very proud of winning this third Pharmapack Award in 4 years. Our connected injector pen Datapen was awarded in 2015 and our smart sensor Easylog in 2016. It is today Onejet’s turn to be rewarded during this major health exhibition. We are confident that this device will bring to our pharma companies partners a new tool for the safety and comfort of their patients’ treatments’’ commented Eric Dessertenne, BIOCORP’s Deputy Chief Executive Officer.

ABOUT PHARMAPACK AWARDS
The Awards, launched alongside the exhibition and conference in 1997, are a yearly returning highlight at Pharmapack Europe.
Each year, the most innovative exhibitors and pharma companies compete to win these prestigious awards. The Awards are judged by a panel of independent industry experts and are handed out during the dedicated ceremony on the show floor.

ABOUT BIOCORP
Founded in 2004 in Issoire (near Clermont-Ferrand), France, BIOCORP is a French company specializing in the development and manufacturing of medical devices and innovative drug delivery systems. It is listed as ‘Innovative Company’ by the French public investment bank Bpifrance. With over twenty years of experience and more than 30 manufactured products, BIOCORP is a key player in the industry, providing drug delivery solutions that meet the evolving needs of patients. Today, BIOCORP continues to innovate in medical plastics, its core business, and to market traditional devices (alternative to aluminum capsules, syringe and vial administration systems) that have been an important source of recurring income. Its solid expertise and capacity to innovate have allowed the company to develop new Internet-connected products, including: the DataPen, a reusable smart injection pen that automatically transmits data to a mobile app, helping patients to manage their treatment; and treatment management add-ons, which adapt to existing delivery devices and are compatible with most injection pens in the market. The company has a team of 48 employees. BIOCORP is listed on Alternext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com
Follow us on Twitter @BIOCORPSystems

(1) source : https://www.transparencymarketresearch.com/pressrelease/global-biologics-market.htm).


© Business Wire 2018
share with twitter share with LinkedIn share with facebook
Latest news on BIOCORP
06/30BIOCORP : Signs Distribution Agreement for Mallya Technology With Roche Diabetes..
BU
06/22BIOCORP : Announces Initiation of Coverage by Gilbert Dupont
BU
06/19BIOCORP : and Théa Sign a Partnership for the Development of Innovative Digital ..
BU
04/09BIOCORP : 2019 annual results
PU
04/09BIOCORP : 2019 Annual Results
BU
04/09BIOCORP : Annual results
CO
04/06BIOCORP : annual earnings release
02/19BIOCORP : Marketing partnership on Mallya with iSage Rx in the field of digital ..
PU
02/19BIOCORP : Marketing Partnership on Mallya with iSage Rx in the Field of Digital ..
BU
02/12BIOCORP : Strong Revenue Growth In 2019
BU
More news
Financials
Sales 2020 15,2 M 17,1 M 17,1 M
Net income 2020 0,60 M 0,67 M 0,67 M
Net cash 2020 1,19 M 1,34 M 1,34 M
P/E ratio 2020 175x
Yield 2020 0,06%
Capitalization 109 M 122 M 122 M
EV / Sales 2019
EV / Sales 2020 7,04x
Nbr of Employees 52
Free-Float 51,3%
Chart BIOCORP
Duration : Period :
Biocorp Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCORP
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price 31,35 €
Last Close Price 26,30 €
Spread / Highest target 21,7%
Spread / Average Target 19,2%
Spread / Lowest Target 16,7%
EPS Revisions
Managers
NameTitle
Eric Dessertenne Chief Executive Officer
Jacques Gardette Chairman
Stéphane Chabanais Chief Financial & Administrative Officer
Alain Marcoz Director-Software Research & Development
Emilie Gardette Director
Sector and Competitors
1st jan.Capitalization (M$)
BIOCORP103.88%122
JOHNSON & JOHNSON-3.36%371 399
ROCHE HOLDING AG4.71%295 898
MERCK & CO., INC.-13.38%198 849
NOVARTIS AG-10.36%192 057
PFIZER, INC.-11.92%191 697